Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure Study

Circulation: Heart Failure

Volumn 13, Issue 7, 2020, Pages 123-131

  Tyl, Benoît ^a   Lopez Sendon, José ^b   Borer, Jeffrey S ^c,d   Lopez De Sa, Esteban ^b   Lerebours, Guy ^e   Varin, Claire ^a   De Montigny, Aurélie ^a   Pannaux, Matthieu ^a   Komajda, Michel ^f  

^a IRIS Institut de Recherches Internationales Servier   (France)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c SUNY Downstate Medical Center   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Health Value 92   (France)

^f SAINT JOSEPH HOSPITAL   (France)

Author keywords

cardiovascular disease; heart failure; hospitalization; ivabradine

Indexed keywords

IVABRADINE;

ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; SINUS RHYTHM; BIOASSAY; COMPARATIVE STUDY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; TREATMENT OUTCOME;

ENDPOINT DETERMINATION; HEART FAILURE; HOSPITALIZATION; HUMANS; OUTCOME ASSESSMENT, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 85088488160     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.119.006720     Document Type: Article

References (36)

1. European Medicines Agency Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure. https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf. Accessed January 31, 2019
2. European Medicines Agency Guideline on clinical investigation of new medicinal products for the treatment of acute coronary syndrome. https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-new-medicinal-products-treatment-acute-coronary-syndrome-first_en.pdf. Accessed January 31, 2019
3. Farb A, Zuckerman BD,. Clinical event adjudication in cardiovascular device trials: an food and drug administration perspective. Am Heart J 2017 191 62-64. doi: 10.1016/j.ahj.2017.05.010
4. Seltzer JH, Turner JR, Geiger MJ, Rosano G, Mahaffey KW, White WB, Sabol MB, Stockbridge N, Sager PT,. Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the cardiac safety research consortium. Am Heart J 2015 169 197-204. doi: 10.1016/j.ahj.2014.11.003
5. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G,. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (ß-Blocker Evaluation of Survival Trial [BEST]). Am Heart J 2010 160 649-654. doi: 10.1016/j.ahj.2010.07.004
6. Seltzer JH, Heise T, Carson P, Canos D, Hiatt JC, Vranckx P, Christen T, Cutlip DE,. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: rationale and best practices. A report from the cardiac safety research consortium. Am Heart J 2017 190 76-85. doi: 10.1016/j.ahj.2017.05.009
7. Kahan BC, Feagan B, Jairath V,. A comparison of approaches for adjudicating outcomes in clinical trials. Trials 2017 18 266. doi: 10.1186/s13063-017-1995-3
8. Girard P, Penaloza A, Parent F, Gable B, Sanchez O, Durieux P, Hausfater P, Dambrine S, Meyer G, Roy PM,. Reproducibility of clinical events adjudications in a trial of venous thromboembolism prevention. J Thromb Haemost 2017 15 662-669. doi: 10.1111/jth.13626
9. Hallén J, Maggioni AP, Lopez-De-Sa E, Turazza FM, Witte K, Erdmann E, Dahlström U, Ertl G, Nielsen OW, Sendon JL,. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial. Eur J Heart Fail 2019 21 1661-1662. doi: 10.1002/ejhf.1574
10. Stuck AK, Fuhrer E, Limacher A, Méan M, Aujesky D,. Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review. J Clin Epidemiol 2014 67 278-284. doi: 10.1016/j.jclinepi.2013.09.011
11. Krumholz-Bahner S, Garibbo M, Getz KA, Widler BE,. An overview and analysis regarding the use of adjudication methods in EU and US drug approvals. Ther Innov Regul Sci 2015 49 831-839. doi: 10.1177/2168479015580382
12. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, Neal B, Reidies H, Santarelli L, Schroyer R,. Do we need to adjudicate major clinical events? Clin Trials 2008 5 56-60. doi: 10.1177/1740774507087972
13. Ghali JK,. Do heart failure trials need an end point committee? Am Heart J 2010 160 571-573. doi: 10.1016/j.ahj.2010.07.005
14. Calvo G, McMurray JJ, Granger CB, Alonso-García Á Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A,. Large streamlined trials in cardiovascular disease. Eur Heart J 2014 35 544-548. doi: 10.1093/eurheartj/eht535
15. Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP,. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart 2017 103 1156-1162. doi: 10.1136/heartjnl-2017-311191
16. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, For the PURSUIT Investigators Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001 2 187-194. doi: 10.1186/cvm-2-4-187
17. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW,. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the reduction of acute coronary syndrome events in a global organization network trial. Am Heart J 2002 143 242-248. doi: 10.1067/mhj.2002.120145
18. Hata J, Arima H, Zoungas S, Fulcher G, Pollock C, Adams M, Watson J, Joshi R, Kengne AP, Ninomiya T, ADVANCE Collaborative Group Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PLoS One 2013 8 e55807. doi: 10.1371/journal.pone.0055807
19. Pogue J, Walter SD, Yusuf S,. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009 6 239-251. doi: 10.1177/1740774509105223
20. Ndounga Diakou LA, Trinquart L, Hróbjartsson A, Barnes C, Yavchitz A, Ravaud P, Boutron I,. Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. Cochrane Database Syst Rev 2016 3 MR000043. doi: 10.1002/14651858.MR000043.pub2
21. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010 376 875-885. doi: 10.1016/S0140-6736(10)61198-1
22. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L,. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the systolic heart failure treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010 12 75-81. doi: 10.1093/eurjhf/hfp154
23. Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006 152 860-866. doi: 10.1016/j.ahj.2006.01.013
24. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008 372 807-816. doi: 10.1016/S0140-6736(08)61170-8
25. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, PARAGON-HF Investigators and Committees Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019 381 1609-1620. doi: 10.1056/NEJMoa1908655
26. O'Connor CM, Fiuzat M, Lindenfeld J, Miller A, Lombardi C, Carson P, Shaw LK, Wang LJ, Connolly P, Mills R,. Mode of death and hospitalization from the second follow-up serial infusions of nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. Am J Cardiol 2011 108 1449-1457. doi: 10.1016/j.amjcard.2011.06.065
27. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Standardized Data Collection for Cardiovascular Trials Initiative (SCTI) 2017 Cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol 2018 71 1021-1034. doi: 10.1016/j.jacc.2017.12.048
28. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinchak RA, Lee KL, MOST Clinical Events Committee Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006 27 260-268. doi: 10.1016/j.cct.2006.02.002
29. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, ESC Scientific Document Group 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016 37 2129-2200. doi: 10.1093/eurheartj/ehw128
30. Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M,. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation 2015 131 43-53. doi: 10.1161/CIRCULATIONAHA.114.012284
31. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 370 1383-1392. doi: 10.1056/NEJMoa1313731
32. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T,. Randomized controlled trials-a matter of design. Neuropsychiatr Dis Treat 2016 12 1341-1349. doi: 10.2147/NDT.S101938
33. Lund LH, Oldgren J, James S,. Registry-based pragmatic trials in heart failure: current experience and future directions. Curr Heart Fail Rep 2017 14 59-70. doi: 10.1007/s11897-017-0325-0
34. Kjøller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, Fischer Hansen J, Kastrup J, Jespersen CM, Hildebrandt P, CLARICOR Trial Group Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial. Am Heart J 2014 168 197-204.e1. doi: 10.1016/j.ahj.2013.12.032
35. Camplain R, Kucharska-Newton A, Loehr L, Keyserling TC, Layton JB, Wruck L, Folsom AR, Bertoni AG, Heiss G,. Accuracy of self-reported heart Failure. The Atherosclerosis Risk in Communities (ARIC) Study. J Card Fail 2017 23 802-808. doi: 10.1016/j.cardfail.2017.09.002
36. Gamerman V, Cai T, Elsäßer A,. Pragmatic randomized clinical trials: best practices and statistical guidance. Health Serv Outcomes Res Method 2019 19 23-35